Shorter launch window with smaller peak requires a different strategy

01/9/2013 | Pharmalot.com

Launching a drug in today's environment once FDA approval is secured presents a unique set of challenges, according to Accenture Life Sciences senior manager Peter Hansen. The shift toward treating smaller populations of patients, who may be down to their last options, erodes peak sales. And aggressive follow-on competitors cut into the period of exclusivity. Manufacturers must shift to accommodate the new reality, starting earlier on their commercialization strategy, replacing large sales forces with peer-to-peer teams and embracing sophisticated targeting of physicians with expert sales reps, Hansen writes.

View Full Article in:

Pharmalot.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY